Holen Sie sich die Stockscreener-App
1.17
12.50%
0.13
Handel nachbörslich:
1.15
-0.02
-1.71%
Schlusskurs vom Vortag:
$1.04
Offen:
$1.05
24-Stunden-Volumen:
256.31K
Relative Volume:
1.03
Marktkapitalisierung:
$25.27M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.32M
KGV:
-2.4294
EPS:
-0.4816
Netto-Cashflow:
$-7.43M
1W Leistung:
+6.36%
1M Leistung:
-0.85%
6M Leistung:
-18.75%
1J Leistung:
-12.03%
1-Tages-Spanne:
$1.05
$1.18
1-Wochen-Bereich:
$0.9827
$1.18
52-Wochen-Spanne:
$0.85
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
Firmenname
NanoViricides Inc
Sektor
Branche
Telefon
203-937-6137
Adresse
1 Controls Drive, Shelton, CT
Compare NNVC vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.17 | 22.46M | 0 | -8.32M | -7.43M | -0.4816 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-16 | Eingeleitet | Alliance Global Partners | Buy |
| 2015-02-11 | Eingeleitet | Midtown Partners | Strong Buy |
NanoViricides Inc Aktie (NNVC) Neueste Nachrichten
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides - ACCESS Newswire
NanoViricides to Present at the 15th Annual BIO-CEO Conference in NYC Tomorrow - AOL.com
Profit Recap: Can NanoViricides Inc continue delivering strong returns2026 Volatility Report & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
NanoViricides seeks FDA’s rare pediatric disease designation for antiviral candidate NV-387ICYMI - Proactive financial news
Macro Review: Should I hold or sell GMREPRA now2026 Spike Watch & Community Consensus Stock Picks - baoquankhu1.vn
Weekly Earnings: Is NanoViricides Inc subject to activist investor interestTake Profit & Real-Time Buy Signal Notifications - baoquankhu1.vn
NNVC Forecast, Price Target & Analyst Ratings | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
Aug Summary: Is NanoViricides Inc undervalued by DCF analysisWeekly Gains Report & Stock Timing and Entry Methods - baoquankhu1.vn
NanoViricides files for Rare Pediatric Disease Designation for Measles Drug - Proactive financial news
Growth Value: Can NanoViricides Inc stock double in the next year2026 Technical Overview & Short-Term Trading Alerts - baoquankhu1.vn
NNVC Ownership | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
Activity Recap: Is NanoViricides Inc forming a bullish divergencePortfolio Value Report & Short-Term Swing Trade Alerts - baoquankhu1.vn
NanoViricides Seeks Rare Pediatric Disease Designation for Measles Treatment Candidate - citybuzz -
Measles Rare Pediatric Disease Drug Designation Application File - GuruFocus
NanoViricides seeks rare pediatric disease status for measles drug NV-387 - Yahoo Finance
About Us - FinancialContent
Aug Shorts: Is NanoViricides Inc forming a breakout pattern2026 Earnings Impact & Short-Term Swing Trade Alerts - baoquankhu1.vn
Small caps wrap: Alvopetro Energy, NanoViricides, New Era Energy & Digital, Digi Power X… - proactiveinvestors.co.uk
NanoViricides to Begin Phase II MPox Clinical Trial in Democratic Republic of Congo - citybuzz -
Small cap wrap: Alvopetro Energy, NanoViricides, New Era Energy & Digital, Digi Power X… - Proactive financial news
NanoViricides to begin Phase II trial of MPox treatment in Congo - Proactive financial news
Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides - ACCESS Newswire
Monkeypox drug trial cleared in Congo as NanoViricides readies dosing - Stock Titan
Tangible book value per share of NanoViricides, Inc. – MUN:NV3P - TradingView
Forecast Cut: Is NanoViricides Inc subject to activist investor interest2026 Patterns & Smart Money Movement Tracker - baoquankhu1.vn
Reviewing NanoViricides (NYSE:NNVC) & Spruce Biosciences (NASDAQ:SPRB) - Defense World
NNVC Should I Buy - Intellectia AI
Growth Recap: Should I hold or sell NanoViricides Inc nowTrade Ideas & Risk Controlled Daily Plans - baoquankhu1.vn
NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete - ACCESS Newswire
NNVC Stock Price, Quote & Chart | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
Aug Retail: Can NanoViricides Inc generate free cash flowEarnings Beat & Real-Time Volume Analysis - baoquankhu1.vn
NanoViricides (NYSE:NNVC) Stock Price Down 4.8% – What’s Next? - Defense World
If You Invested $1,000 in Nanoviricides (NNVC) - Stock Titan
EBITDA per share of NanoViricides, Inc. – FWB:NV3P - TradingView
Volume Recap: Can NanoViricides Inc grow without external funding2026 Momentum Check & Consistent Return Strategy Ideas - baoquankhu1.vn
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - Beaver County Times
In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides - The Register-Guard
NanoViricides, Inc. Has Filed its Quarterly ReportSubsequent Raise Has Fortified Fiscal Position - The Asheville Citizen Times
NanoViricides Completes Manufacturing of NV-387 Oral Gummies, Prepares for Phase II Monkeypox Trial - citybuzz -
Aug Setups: Can NanoViricides Inc continue delivering strong returns2026 EndofMonth & Stepwise Trade Execution Plans - baoquankhu1.vn
Small cap wrap: NanoViricides, Millennial Potash, Gunnison Copper, Century Lithium… - Proactive Investors
NanoViricides completes manufacturing of NV-387 oral drug ahead of Phase II mpox trial - Yahoo! Finance Canada
Antiviral NV-387 heads to Phase II mpox trial with new gummy form - Stock Titan
Jobs Data: Can NanoViricides Inc continue delivering strong returnsMarket Volume Report & Community Verified Trade Signals - baoquankhu1.vn
Sell Signal: Is NanoViricides Inc subject to activist investor interest2025 Investor Takeaways & Low Risk Growth Stock Ideas - baoquankhu1.vn
NNVC Earnings History & Surprises | EPS & Revenue Results | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
Finanzdaten der NanoViricides Inc-Aktie (NNVC)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):